Skip to main content
. 2014 Jan 29;99(5):E754–E765. doi: 10.1210/jc.2013-3734

Table 1.

Epidemiological, Histological, and Clinical Data of Patients With FCDTCs Included in the Study

Total PTC FTC PDTC ATC
Total number 469 332 70 31 36
Age at diagnosis, y, n 469 332 70 31 36
    Mean, y 48.2 ± 16.9 44.8 ± 15.6 51.8 ± 16.4 53.2 ± 18.4 68.7 ± 10.4
    <45 211 (45.0) 178 (53.6) 23 (32.9) 8 (25.8) 2 (5.6)
    ≥45 258 (55.0) 154 (46.4) 47 (67.1) 23 (74.2) 34 (94.4)
Gender, n 459 327 68 29 35
    Female 342 (74.5) 254 (77.7) 50 (73.5) 16 (55.2) 22 (62.9)
    Male 117 (25.5) 73 (22.3) 18 (26.5) 13 (44.8) 13 (37.1)
Tumor size, cm, n 418 315 61 26 16
    <2a 151 (36.1) 142 (45.0) 7 (11.5) 2 (7.7) 0
    2–4 161 (38.5) 129 (41.0) 23 (37.7) 7 (26.9) 2 (12.5)
    >4 106 (25.4) 44 (14.0) 31 (50.8) 17 (65.4) 14 (87.5)
Extrathyroidal extension, n 373 268 49 20 36
    Present 231 (61.9) 176 (65.7) 8 (16.3) 12 (60.0) 35 (97.2)
Vascular invasion, n 325 257 53 8 7
    Present 157 (48.3) 103 (40.1) 39 (73.6) 8 (100.0) 7 (100.0)
Lymph node metastasis, n 391 298 47 24 22
    Present 234 (59.8) 202 (67.8) 8 (17.0) 14 (58.3) 10 (45.5)
Distant metastasis, n 337 263 31 20 23
    Present 76 (22.6) 36 (13.7) 8 (25.8) 14 (70.0) 18 (78.3)
Stage (sixth UICC/AJCC), n 310 225 29 20 36
    I 134 (43.2) 124 (55.1) 8 (27.6) 2 (10.0) 0
    II 36 (11.6) 25 (11.1) 8 (27.6) 3 (15.0) 0
    III 45 (14.5) 36 (16.0) 5 (17.2) 4 (20.0) 0
    IV 95 (30.7) 40 (17.8) 8 (27.6) 11 (55.0) 36 (100.0)
TERT promoter, n 469 332 70 31 36
    Wild-type 411 (87.6) 307 (92.5) 58 (82.9) 22 (71.0) 24 (66.7)
    Mutation 58 (12.4) 25 (7.5) 12 (17.1) 9 (29.0) 12 (33.3)

Abbreviations: n, number of patients with available data for each feature; UICC, Union for International Cancer Control. Numbers in parentheses represent percentages within each category.

a

Number of microcarcinomas (≤1.0 cm): total, 47 (11.2%); PTC, 43 (13.7%); FTC, 4 (6.6%); PDTC, 0, ATC, 0.